Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 4/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 1/20 | 0.64 |
| ▸ | MGLL | Q99685 | 1/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093425 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL31035964 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL29263641 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL9219707 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL916601 | 0.98 | TDP1 (0.96) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL45050 | 0.93 | TDP1 (0.86) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL30371663 | 0.93 | TDP1 (0.86) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL9021226 | 0.91 | TDP1 (0.82) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL24340266 | 0.88 | TDP1 (0.79) | TDP1L3MBTL1GSK3AGSK3BACHE | |
| SCHEMBL3792244 | 0.87 | TDP1 (0.77) | TDP1L3MBTL1GSK3AGSK3BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-3143009-B1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2019-09-18 | — | — | EP | disclosed |
| EP-3143009-B1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2019-09-18 | — | — | EP | disclosed |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-06-29 | — | — | US | disclosed |
| EP-3143009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | Fondazione Istituto Italiano di Tecnologia (IT) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015173169-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015173169-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-11-19 | — | — | WO | disclosed |
| US-5998433-A | THERAPY FOR HYPERLIPIDEMIA; ATHEROSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| CN-1160403-A | Substd. heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-09-24 | — | — | CN | disclosed |
| EP-0785939-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011201-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| US-5061720-A | ANTIINFLAMMATORY AGENTS FOR TOPICAL APPLICATION TO SKIN | A. H. ROBINS COMPANY, INC. (US) | 1991-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182009-A1 | SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | TDP1 2480/4885L3MBTL1 4346/4885GSK3A 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.